Current and future treatments for cognitive deficits in dementia
- 1 February 2000
- journal article
- research article
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 2 (1) , 20-23
- https://doi.org/10.1007/s11920-000-0037-z
Abstract
In this article, we primarily focus on the treatment approaches currently marketed and in advanced stages of development for Alzheimer’s disease (AD). Amyloid plaques and neurofibrillary tangles remain the pathologic hallmarks of AD, and much progress has been made in unraveling the molecular biology of these changes. In addition, there is also intense research into inflammatory and oxidative mechanisms as well as vascular and neurochemical alterations in AD. Therapies targeted at these mechanisms are discussed.Keywords
This publication has 11 references indexed in Scilit:
- Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil ExperienceJournal of Geriatric Psychiatry and Neurology, 1999
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- Current Status of Antioxidant Therapy for Alzheimer's DiseaseJournal of the American Geriatrics Society, 1998
- The Efficacy of Ginkgo biloba on Cognitive Function in Alzheimer DiseaseArchives of Neurology, 1998
- Combination Therapy for Early Alzheimer's Disease: What Are We Waiting for?Journal of the American Geriatrics Society, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's DiseaseNew England Journal of Medicine, 1997
- Effect of oestrogen during menopause on risk and age at onset of Alzheimer's diseaseThe Lancet, 1996
- Searching for drugs that combat Alzheimer's.1996
- Clinical trial of indomethacin in Alzheimer's diseaseNeurology, 1993